2.06
+0.09(+4.57%)
Currency In USD
| Previous Close | 1.97 |
| Open | 1.97 |
| Day High | 2.1 |
| Day Low | 1.94 |
| 52-Week High | 3.39 |
| 52-Week Low | 0.79 |
| Volume | 2.33M |
| Average Volume | 3.15M |
| Market Cap | 91.5M |
| PE | -2.45 |
| EPS | -0.84 |
| Moving Average 50 Days | 1.39 |
| Moving Average 200 Days | 1.58 |
| Change | 0.09 |
If you invested $1000 in Outlook Therapeutics, Inc. (OTLK) since IPO date, it would be worth $3.02 as of December 04, 2025 at a share price of $2.06. Whereas If you bought $1000 worth of Outlook Therapeutics, Inc. (OTLK) shares 5 years ago, it would be worth $88.79 as of December 04, 2025 at a share price of $2.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 24, 2025 2:05 PM GMT
Live webcast fireside chat on Tuesday, December 2nd at 10:00 AM ETISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for t
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
GlobeNewswire Inc.
Nov 13, 2025 1:30 PM GMT
Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025 ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab f
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
GlobeNewswire Inc.
Nov 03, 2025 1:35 PM GMT
ISELIN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has re-submit